Related Experiment Videos
[Cefixime. Microbiologic, kinetic and clinical profile]
Abstract:
The microbiological, kinetic and clinical profile of cefixime, a IIIrd generation cephalosporin, administered orally, is presented. Cefixime is highly active versus Gram-negative aerobic bacteria while, with respect to Gram-positive bacteria, it is only active against Str. pneumoniae, Str. pyogenes, Str. agalactiae, and Str. bovis. It has no action against anaerobics. Endowed with good kinetics, cefixime possesses a favourable tissue distribution. Cefixime is highly indicated in infections of the upper and lower airways where the aethiology is prevalently due to Str. pneumoniae, H. influenzae and B. catarrhalis, that are extremely sensitive to the antibiotic. It is concluded that the therapeutic armamentarium has been enriched by a new, highly active antibiotic that, administered in a monodese/die, ca satisfy patient compliance.
Insights
Cefixime, a third-generation cephalosporin antibiotic, shows high activity against Gram-negative bacteria and specific Gram-positive strains. Its favorable pharmacokinetics and once-daily dosing make it a valuable option for respiratory tract infections.
Area of Science:
- Microbiology
- Pharmacology
- Clinical Medicine
Context:
- Evaluation of cefixime, an oral third-generation cephalosporin.
- Assessment of its microbiological spectrum, pharmacokinetic properties, and clinical utility.
Purpose:
- To present the comprehensive profile of cefixime.
- To highlight its efficacy and suitability for specific infections.
Summary:
- Cefixime exhibits potent activity against Gram-negative aerobic bacteria and key Gram-positive cocci (e.g., Streptococcus pneumoniae).
- It demonstrates no activity against anaerobic bacteria.
- The antibiotic possesses favorable pharmacokinetic properties, including good tissue distribution, and is indicated for upper and lower respiratory tract infections caused by susceptible pathogens like H. influenzae and B. catarrhalis.
Impact:
- Cefixime expands therapeutic options for bacterial infections.
- Its once-daily dosing regimen enhances patient compliance.
- Provides a new, effective antibiotic for common respiratory infections.